AblinJ., VittekJ.: On the mechanism of the anti-androgenic effect of medroxyprogesterone acetate. Endocrinology, 93; 417–422 (1973).
3.
ArduinoL. J., GlucksmanM. A.: Lymph node metastases in early carcinoma of the prostate. J. Urol., 88; 91–93 (1962).
4.
BarnesR. W., NinanC. A.: Carcinoma of the prostate: biopsy and conservative therapy. J. Urol., 108; 897–900 (1972).
5.
BeltE., SchroederF. H.: Total perineal prostatectomy for carcinoma of the prostate. J. Urol., 107; 91–96 (1972).
6.
BerlinB. B., CarnwellP. M., ConnellyR. R., EisembergH.: Radical perineal prostatectomy for carcinoma of the prostate. J. Urol., 99; 97–101 (1968).
7.
BlackardC. E., DoeR. P., MellingerG. T., ByarD. P.: Incidence of cardiovascular disease and death in patients receiving diethyl-stilboestrol for carcinoma of prostate. Cancer, 26; 249–256 (1970).
BracciU.: Our present procedures in the treatment of prostatic cancer, in: Hormonal therapy of prostatic cancer, 1977.
10.
ByarD. P., Vacurg: Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative menagement. J. Urol., 108; 908–913 (1972).
11.
CatalonaW. J., ChretienP. B., TraharrE. E.: Abnormalities of all mediated immunocompetence in genitourinary cancer. J. Urol., 112; 373–377 (1974).
12.
CulpO. S., MeyerJ. J.: Radical prostatectomy in the treatment of prostatic cancer. Cancer, 32; 1113–1118 (1973).
13.
EaganP.: Cancer Chem. Rep. Urol., 60; 115 (1970).
14.
EmmettL., GreenL. F., PapantoniouA.: Endocrine therapy of the prostate gland. J. Urol., 83; 471–484 (1960).
15.
FergussonJ. D.: The doubtfully malignant prostate. Brit. J. Surg., 52; 746–750 (1965).
16.
Eortc: Comunicazione personale (1976).
17.
Eortc: Comunicazione personale (1977).
18.
FlocksR. M.: The treatment of stage C prostatic cancer with special reference to combined surgical and radiation therapy. J. Urol., 109; 461–463 (1973).
19.
FlocksR. H., ChengS. F.: Combination therapy for prostatic carcinoma. J. Iowa Med. Soc., 58; 125–129 (1968).
20.
FlocksR. H., CulpD. A., PortoR.: Lymphatic spread from prostatic cancer. J. Urol., 81; 194–196 (1959).
21.
FlocksR. H., UrichV. C., PatelC A., OpitzJ. M.: Studies on the antigenic properties of prostatic tissue. J. Urol., 84; 134–136 (1960).
22.
GellerJ., FishmanJ., CantorT. L.: Effect of cyproterone acetate on clinical, endocrine and pathological features of benign prostatic hypertrophy. J. Steroid Biochem., 6; 837–843 (1975).
23.
GiorgiE. P., ShirleyI. M., GrantJ. K., StewartJ. C.: Androgen dynamics in vitro in the human prostate gland. Effect of Cyproterone and Cyproterone acetate. J Biochem., 132; 465–474 (1973).
HudsonH. C., HowlandR. L.: Radical retropubic prostatectomy for cancer of the prostate. J. Urol., 108; 944–947 (1972).
26.
JewettH. L., EgglestonJ. C., YawnD. M.: Radical prostatectomy in the management of carcinoma of the prostate. J. Urol., 107; 1034–1040 (1972).
27.
JonssonG., HogbergB.: Treatment of advanced prostatic carcinoma with Estracyt. Scand. J. Urol. & Nephrol., 5; 103–107 (1971).
28.
KontturiM., KiviniittyK.: Radiostrontium in the early diagnosis of bone metastases in patients with prostatic carcinoma. Scand. J. Urol. & Nephrol., 5; 210–214 (1971).
29.
LernerL. J., BrennanD. M., YiacasE., De PhillipoM., BornamA.: Pregnancy maintenance in ovariectomized rats with 169–17 dihydroxy-progesterone derivatives and other progestogens. Endocrinology, 70; 283–287 (1972).
30.
MellingerG. T., CleasonD. F., BailarJ.: The histology and prognosis of prostatic cancer. J. Urol., 97; 331–337 (1967).
31.
NesbitR. M., BaumW. C.: Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J.A.M.A., 143; 1317–1320 (1950).
32.
NeumanF., Jon Berswordt-WallrabeR., ElgerW., SteinbeckH., HahnJ. D., KramerM.: Aspect of androgen-dependent events as studies by anti-androgens. Recent Progr. Hormone Res., 26; 337 (1970).
33.
OrestanoF., AltweinJ. E., KnapsteinP., BandhauerK.: Mode of action of progesterone gestonorone capronate (Depostat) and ciproterone acetate (Androcur) on the metabolism of testosterone in human prostatic adenoma: in vitro and in vivo investigations. J. Steroid Biochen., 6; 845–851 (1975).
34.
RaflaS., JohnsonR.: The treatment of advanced prostatic carcinoma with medroxy progesterone. Curr. Ther. Res., 16; 961–967 (1974).
35.
RayG. R., CassadyJ. R., MacshawM. A.: Definitive radiation theraphy of carcinoma of the prostate. Radiology, 106; 407–418 (1973).
36.
RayR. R., NathanB. E., BealesJ. S. M., ChrisholnG. D.: 18-Fluorine total body scans in patients with carcinoma of prostate. Brit. J. Urol., 43; 58–64 (1971).
37.
RivarolaM. A., CamachoA. M., MigeonC. J.: Effect of treatment with medroxy-progesterone acetate on testicular function. J. Clinic. Endocr. Metabol., 28; 679–684 (1968).
38.
RobinsonM. R. G., NakhlaL. S., WhitakerR. H.: A new concept in the management of carcinoma of the prostate. Brit. J. Urol., 43; 728–732 (1971).
39.
ScottW. W., BoydH. L.: Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate. J. Urol., 101; 86–92 (1969).
40.
TanS. Y., AntonipillaiI., Pearson MurphyB. E.: Inibition of testosterone metabolism in the human prostate. J. Clin. Endocr. & Metab., 39; 936–941 (1974).
41.
Vacurg: Carcinoma of prostate: a continuing clinical study. J. Urol., 91; 590–594 (1964).
42.
Vacurg: Carcinoma of the prostate: treatment comparisons. J. Urol., 98; 516–520 (1967).
43.
VickeryA. L., KerrW. S.: Cancer of the prostate treated by radical prostatectomy. Cancer, 16; 1598–1608 (1963).
44.
WhitmoreW. F.Jr., HilarisB., GrabstaldH.: Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J. Urol., 108; 918–920 (1972).
45.
WhitmoreW. F., McKenzieA. R.: Experiences with various operative procedures for the total excision of prostatic cancer. Cancer, 12; 396–405 (1959).
46.
YoshidaK.: Ultrastructure of epithelium of prostatic anterior lobe in cats. Long-term observation of Medroxy-progesterone-acetate induced changes. Jap. J. Urol., 66; 383–399 (1975).